{"id":"carbamazepine-controlled-release","safety":{"commonSideEffects":[{"rate":"30-40","effect":"Dizziness"},{"rate":"15-25","effect":"Ataxia"},{"rate":"25-35","effect":"Diplopia"},{"rate":"10-20","effect":"Nausea"},{"rate":"5-15","effect":"Rash"},{"rate":"5-10","effect":"Hyponatremia"},{"rate":"0.5-1","effect":"Agranulocytosis"}]},"_chembl":{"chemblId":"CHEMBL108","moleculeType":"Small molecule","molecularWeight":"236.27"},"_fixedAt":"2026-03-30T13:29:37.597893","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Carbamazepine acts primarily as a voltage-gated sodium channel blocker, which decreases the influx of sodium ions into neurons and stabilizes the inactive state of the channel. This mechanism reduces the frequency of action potentials and prevents the spread of abnormal electrical activity in the brain. The controlled-release formulation extends drug delivery over time, providing more stable plasma concentrations and potentially improved tolerability compared to immediate-release formulations.","oneSentence":"Carbamazepine is an anticonvulsant that stabilizes neuronal membranes by blocking sodium channels, reducing repetitive neuronal firing and propagation of seizure activity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:04:55.207Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Epilepsy / seizure disorders"},{"name":"Trigeminal neuralgia"},{"name":"Bipolar disorder"}]},"_fixedFields":["modality→Biologic"],"trialDetails":[{"nctId":"NCT01243177","phase":"PHASE3","title":"Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older","status":"COMPLETED","sponsor":"UCB BIOSCIENCES GmbH","startDate":"2011-04","conditions":"Epilepsy, Monotherapy","enrollment":888},{"nctId":"NCT01465997","phase":"PHASE3","title":"Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older","status":"COMPLETED","sponsor":"UCB BIOSCIENCES GmbH","startDate":"2012-05","conditions":"Epilepsy, Monotherapy","enrollment":551},{"nctId":"NCT01954121","phase":"PHASE3","title":"Open-label, Randomized, Active-controlled Study of LEV Used as Monotherapy in Patients With Partial-Onset Seizures","status":"COMPLETED","sponsor":"UCB Pharma SA","startDate":"2013-09","conditions":"Epilepsy, Partial Seizures","enrollment":436},{"nctId":"NCT01162460","phase":"PHASE3","title":"Efficacy and Safety of Eslicarbazepine Acetate as Monotherapy for Patients With Newly Diagnosed Partial-onset Seizures","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2010-12","conditions":"Epilepsy","enrollment":815},{"nctId":"NCT00175903","phase":"PHASE3","title":"Levetiracetam Versus Standard Antiepileptic Drugs (Carbamazepine and Valproate) Used as Monotherapy in Patients With Newly Diagnosed Epilepsy","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2005-02","conditions":"Epilepsy","enrollment":1701},{"nctId":"NCT02208492","phase":"PHASE4","title":"The Effects on Cognitive Function of Levetiracetam (Keppra®) Compared to Carbamazepine (Tegretol®, Carmazepine®) as Monotherapy for Children With Partial Seizure; A Multicentric Randomized Controlled Study","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2011-09","conditions":"Focal Epilepsy","enrollment":75},{"nctId":"NCT02132897","phase":"PHASE1","title":"Fed Bioequivalence Study of CBZ Formulations","status":"COMPLETED","sponsor":"Center for Clinical Pharmacology Research Bdbeq S.A.","startDate":"2014-05","conditions":"Bio-equivalence Study, Fed Conditions","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Tegretol® Retard Tablets 200 mg"],"phase":"phase_3","status":"active","brandName":"Carbamazepine-Controlled Release","genericName":"Carbamazepine-Controlled Release","companyName":"UCB BIOSCIENCES GmbH","companyId":"ucb-biosciences-gmbh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Carbamazepine-Controlled Release is a small molecule that acts as a sodium channel alpha subunit blocker, classified as a blocker. It is used to treat conditions such as epilepsy, partial seizures, and focal epilepsy, often as monotherapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}